{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Minor Response (MR): A minor response (MR) is defined 25-49% reduction in serum IgM levels.","groups":[{"description":"ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles\n\nABT199: Oral BCL-2 antagonist","id":"OG000","title":"ABT199"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"1 participant was censored from the response analysis after it was determined that he had IgM Myeloma rather than Waldenstrom's macroglobulinemia.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Participants With Minor Response","type":"SECONDARY","unitOfMeasure":"Participants"}